---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-007942"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:21:18.921701+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics shareholders approve all five proposals at 2024 annual meeting

## Summary
- Elected Garo H. Armen and Brian J. Corvese as Class III directors with ~1.87M and ~1.85M for votes.
- Approved repricing of outstanding stock options: 1,803,833 for, 184,143 against, 70,373 abstain.
- Ratified MaloneBailey LLP as auditor for FY2024: 3,492,771 for, 81,987 against, 72,564 abstain.
- Approved issuance of common stock warrant shares from Oct 2024 agreements: 1,928,277 for, 58,942 against.
- Approved amendment to 2016 Equity Plan allowing option repricing without shareholder approval: 1,803,817 for.

## SEC filing metadata
- accession: 0001493152-25-007942
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315225007942/0001493152-25-007942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315225007942/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-007942
- JSON: https://secwatch.observer/filing/0001493152-25-007942.json
- Plain text: https://secwatch.observer/filing/0001493152-25-007942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.